SNMMI/EANM/ACNM Procedure Standard/Procedure Guideline on the Use of Molecular Imaging for Renal Mass Characterization
Journal of Nuclear Medicine · 2025
DOI: 10.2967/jnumed.125.271332 ↗Kurz gefasst
Leitlinie in der Zeitschrift Journal of Nuclear Medicine, 2025. Verfasst von Steven P Rowe und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiology, University of Texas Southwestern Medical Center, Dallas, Texas; steven.rowe@utsouthwestern.edu. Hauptthemen laut MEDLINE: Molecular Imaging, Kidney Neoplasms, Nuclear Medicine. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 48 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS.
Abstract (Originalsprache)
Anatomic imaging of renal masses provides limited information on the histology or likely aggressiveness of the tumor, leading to the use of invasive procedures such as renal mass biopsy or empiric partial or radical nephrectomy. Molecular imaging can assist in risk stratification of indeterminate renal masses, potentially contributing to optimal patient decision-making. Two primary approaches have been explored for renal mass molecular imaging. The first is the use of agents that target carbonic anhydrase IX (CAIX), a cell-surface protein that is over-expressed on clear cell renal cell carcinoma (ccRCC) and generally not expressed on other renal tumors. A recent phase III trial (ZIRCON) is widely believed to have laid the groundwork for United States Food and Drug Administration approval of the CAIX monoclonal antibody 89Zr-girentuximab. The second approach is the use of mitochondrial imaging agents, most notably 99mTc-sestamibi, which are lipophilic cations that accumulate in tumors with an abundance of mitochondria with negative charge potential (e.g., oncocytomas and other benign/indolent lesion) and do not accumulate in tumors with multidrug resistance pumps (e.g., ccRCC). The complementary information from 89Zr-girentuximab and 99mTc-sestamibi can provide improved risk stratification. Further, emerging new targeted radiotracers and techniques such as imaging biomarker discovery with artificial intelligence will bolster those concepts. In this manual, we synthesize key data into a recommended approach.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Radiology, University of Texas Southwestern Medical Center, Dallas, Texas; steven.rowe@utsouthwestern.edu.
- Department of Urology, University of California, Los Angeles, California.
- Urologic Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland.
- Department of Urology, Royal Free Hospital, London, United Kingdom, and The Netherlands Cancer Institute, Amsterdam, The Netherlands.
- Bay Imaging Consultants Medical Group, Inc., Walnut Creek, California.
- Division of Nuclear Medicine and Theranostics, Department of Diagnostic Imaging, Roswell Park Comprehensive Cancer Center, Buffalo, New York.
Förderung
- NCI NIH HHS
Zitieren
APA
Rowe, S. P., Shuch, B. M., Ball, M. W., Bex, A., Javadi, M. S., Klitzke, A., Goffin, K., Mulders, P., Pandit-Taskar, N., Parihar, A. S., Viglianti, B. L., Gorin, M. A., & Herrmann, K. (2025). SNMMI/EANM/ACNM Procedure Standard/Procedure Guideline on the Use of Molecular Imaging for Renal Mass Characterization. Journal of Nuclear Medicine. https://doi.org/10.2967/jnumed.125.271332
Vancouver
Rowe SP, Shuch BM, Ball MW, Bex A, Javadi MS, Klitzke A, et al. SNMMI/EANM/ACNM Procedure Standard/Procedure Guideline on the Use of Molecular Imaging for Renal Mass Characterization. Journal of Nuclear Medicine. 2025. doi:10.2967/jnumed.125.271332
BibTeX
@article{Rowe2025,
author = {Rowe, Steven P and Shuch, Brian M and Ball, Mark W and Bex, Axel and Javadi, Mehrbod S and Klitzke, Alan and Goffin, Karolien and Mulders, Peter and Pandit-Taskar, Neeta and Parihar, Ashwin Singh and Viglianti, Benjamin L and Gorin, Michael A and Herrmann, Ken},
title = {SNMMI/EANM/ACNM Procedure Standard/Procedure Guideline on the Use of Molecular Imaging for Renal Mass Characterization},
journal = {Journal of Nuclear Medicine},
year = {2025},
doi = {10.2967/jnumed.125.271332}
}
EUVIMED